Published in Oncogene on June 20, 2011
Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A (2011) 2.46
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
Molecular pathogenesis and progression of prostate cancer. Semin Oncol (2013) 1.08
Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev (2013) 1.08
The genomic landscape of prostate cancer. Front Endocrinol (Lausanne) (2012) 1.07
NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128. Oncogenesis (2013) 0.97
Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget (2015) 0.94
RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov (2014) 0.93
Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev (2014) 0.93
Current mouse and cell models in prostate cancer research. Endocr Relat Cancer (2013) 0.92
Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. Am J Clin Exp Urol (2014) 0.91
Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis. Oncogene (2013) 0.91
DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene (2014) 0.90
Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer. BMC Med Genomics (2014) 0.83
Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival. Oncogene (2015) 0.82
Antioxidant treatment promotes prostate epithelial proliferation in Nkx3.1 mutant mice. PLoS One (2012) 0.80
Prostate cancer induced by loss of Apc is restrained by TGFβ signaling. PLoS One (2014) 0.79
Profiling prostate cancer. Proc Natl Acad Sci U S A (2011) 0.78
Recent progress in mouse models for tumor suppressor genes and its implications in human cancer. Clin Med Insights Oncol (2013) 0.78
MCT-1 expression and PTEN deficiency synergistically promote neoplastic multinucleation through the Src/p190B signaling activation. Oncogene (2014) 0.78
Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer. Cancer Res (2015) 0.77
Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. J Exp Med (2016) 0.76
Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes (Basel) (2017) 0.75
Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids. Oncotarget (2017) 0.75
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer (1953) 11.45
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet (2001) 9.55
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science (2001) 6.84
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol (2004) 5.43
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res (1999) 3.29
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol (2009) 2.69
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer (2007) 2.65
Combinatorial patterns of somatic gene mutations in cancer. FASEB J (2008) 2.40
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol (2009) 2.13
Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene (1998) 1.97
Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res (1998) 1.83
Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst (1998) 1.81
Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer (2008) 1.66
MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65
Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol (2010) 1.61
Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer (2007) 1.60
Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res (2001) 1.59
p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res (1993) 1.59
Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med (2001) 1.55
p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst (1993) 1.54
Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol (2002) 1.43
Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. Hum Pathol (2001) 1.37
Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer (1992) 1.34
Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet (2009) 1.16
p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol (1992) 1.06
An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res (1996) 1.03
Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma. Proc Natl Acad Sci U S A (2009) 1.02
Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res (2003) 1.00
p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst (1994) 0.99
Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol Oncol (2004) 0.98
p53 oncogene mutations in human prostate cancer specimens. J Urol (1994) 0.98
Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol (1995) 0.92
Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Br J Urol (1991) 0.89
p53 gene alterations in human prostate carcinoma. J Urol (1993) 0.87
Transgenic mice for Cre-inducible overexpression of the oncogenes c-MYC and Pim-1 in multiple tissues. Genesis (2006) 0.87
Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer (1994) 0.84
Expression of PTEN in malignant and non-malignant human prostate tissues: comparison with p27 protein expression. J Pathol (2004) 0.83
Evaluation of biomarkers in breast and prostate cancer. J Cell Biochem Suppl (1994) 0.82
Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res (2001) 0.81
p53 mutations occur in clinical, but not latent, human prostate carcinoma. Jpn J Cancer Res (1995) 0.80
EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem (2000) 1.80
Molecular cloning and characterization of Pals, proteins associated with mLin-7. J Biol Chem (2000) 1.64
A neuronal model of Alzheimer's disease: an insight into the mechanisms of oxidative stress-mediated mitochondrial injury. Neuroscience (2008) 1.43
Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene (2010) 1.39
A case of chromonychia with hyperbilirubinemia. J Eur Acad Dermatol Venereol (2007) 1.08
Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer (1991) 1.08
Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene (2011) 1.02
Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer (1993) 0.99
Quantitative amplification of genomic DNA from histological tissue sections after staining with nuclear dyes and laser capture microdissection. J Mol Diagn (2001) 0.97
Inhibition of NF-AT-dependent transcription by NF-kappa B: implications for differential gene expression in T helper cell subsets. Proc Natl Acad Sci U S A (1995) 0.96
Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst (1993) 0.96
Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol (1994) 0.92
Treatment of unstable distal radius fractures with cancellous allograft and external fixation. J Hand Surg Am (1999) 0.91
Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. Cancer (1994) 0.89
NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) (1996) 0.89
Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. Am J Clin Oncol (1999) 0.88
Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin. J Clin Oncol (1997) 0.87
Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst (1991) 0.83
Clinical pharmacology and tissue disposition studies of 131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88. Cancer Immunol Immunother (1994) 0.83
A Phase II safety and effect on time to tumor progression study of intratumoral light infusion technology using talaporfin sodium in patients with metastatic colorectal cancer. J Surg Oncol (2007) 0.82
Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53. Biotech Histochem (2012) 0.81
Effects of binge ethanol administration on the behavioral outcome of rats after lateral fluid percussion brain injury. J Neurotrauma (2001) 0.79
Use of sonography in diagnosing acute appendicitis: comparison of a teaching hospital and a community hospital. Acad Radiol (1996) 0.75
A phase I evaluation of chronotropic delivery of floxuridine by hepatic arterial infusion in patients with metastatic colorectal cancer. Oncol Rep (1996) 0.75
Vitamin B complex for chloroquine-induced pruritus. Trans R Soc Trop Med Hyg (1991) 0.75